Efficacy of 0.1% triamcinolone with nanoliposomal carrier formulation in orabase for oral lichen planus patients: A clinical trial

IntroductionLichen planus (LP) is a chronic mucocutaneous disease, with different clinical subtypes. The erythematous-ulcerative type is accompanied by pain and burning sensation. Topical or systemic corticosteroid therapy is among the common treatments. No evidence is available supporting the superiority of any specific type or dose of treatment. Nano-drugs have recently been used for the management of oral lesions. This study sought to compare the anti-inflammatory effects of 0.1% triamcinolone acetonide in Orabase® with and without nanoliposomal carriers on oral lichen planus (OLP).MethodsThis randomized clinical trial was performed on 60 patients with erythematous-ulcerative OLP. Formulations of 0.1% triamcinolone acetonide with and without nanoliposomal carriers in Orabase were used 3 times a day for a month in case and control groups, respectively. Pain intensity by linear Visual Analog Scale [1], [2], [3], [4], [5], [6], [7], [8], [9] and [10] and cross sectional area of the lesions by a grid paper (mm2) were measured before and one, two and four weeks after treatment. Data were analyzed using t-test, chi-square, Fisher’s Exact, Mann–Whitney and Wilcoxon Singed-Rank tests.ResultsThe pain intensity and size of oral lesions decreased statistically by each drug formulation (P ≤ 0.001). Also there were significant differences between the two formulations after two and four weeks of treatment (P < 0.05).ConclusionBased on the results, the efficacy 0.1% triamcinolone acetonide with nanoliposomal carrier formulations was more effective than 0.1% triamcinolone acetonide without nanoliposomal for OLP.